Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cell Procurement

Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma

Bone Marrow Transplantation volume 40, pages 111–118 (2007)Cite this article

Abstract

Hematopoietic growth factors alone or in combination with myelosuppressive chemotherapy are used to mobilize peripheral blood stem cells for autologous transplantation. To identify characteristics of successful mobilization with granulocyte colony-stimulating factor (G-CSF) alone and to study the impact of immediate chemotherapy mobilization following G-CSF mobilization, we treated 175 chemotherapy sensitive lymphoma patients with G-CSF (G) mobilization and leukapheresis followed by chemotherapy plus G-CSF (CG) mobilization and leukapheresis and then autologous transplantation. Patients with stage I/II disease at diagnosis and ⩽5 years from diagnosis were more likely to mobilize successfully with G-CSF alone (G). CG mobilization led to superior stem cell yields compared to the preceding mobilization with G (median 2.37 vs 1.37 ( × 106CD34+ cells/kg); P<0.0001). Patients (n=58, 33%) with successful G-CSF mobilization (⩾2 × 106 CD34+ cells/kg) had quicker platelet recovery and improved progression free and overall survival compared to patients who had adequate collection only after chemotherapy mobilization or to those who failed to collect an adequate graft with either type of mobilization. The poor clinical outcome of patients with difficult mobilization using either method identifies them as a high-risk group who might benefit from alternative therapies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  Google Scholar 

  2. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–357.

    CAS  PubMed  Google Scholar 

  3. Chao NJ, Schriber JR, Grimes K, Long GD, Negrin RS, Raimondi CM et al. Granulocyte colony-stimulating factor ‘mobilized’ peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031–2035.

    CAS  PubMed  Google Scholar 

  4. Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059–2064.

    Article  CAS  Google Scholar 

  5. Watts MJ, Sullivan AM, Jamieson E, Pearce R, Fielding A, Devereux S et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535–546.

    Article  CAS  Google Scholar 

  6. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–3794.

    CAS  PubMed  Google Scholar 

  7. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547–2555.

    Article  CAS  Google Scholar 

  8. Gordan LN, Sugrue MW, Lynch JW, Williams KD, Khan SA, Wingard JR et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003; 44: 815–820.

    Article  CAS  Google Scholar 

  9. Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37: 719–724.

    Article  CAS  Google Scholar 

  10. Stockerl-Goldstein KE, Reddy SA, Horning SF, Blume KG, Chao NF, Hu WW et al. Favorable treatment outcome in non-Hodgkin's lymphoma patients with ‘poor’ mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant 2000; 6: 506–512.

    Article  CAS  Google Scholar 

  11. Kaplan E, Meier P . Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  12. Cox D . Regression models adn life-tables (with discussion). J R Stat Soc 1972; B34: 187–220.

    Google Scholar 

  13. Gray R . A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141–1154.

    Article  Google Scholar 

  14. Weaver C, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–3969.

    CAS  Google Scholar 

  15. Boeve S, Strupeck J, Creech S, Stiff PJ . Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost. Bone Marrow Transplant 2004; 33: 997–1003.

    Article  CAS  Google Scholar 

  16. Chabannon C, Le Corroller AG, Viret F, Eillen C, Faucher C, Moatti JP et al. Cost-effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation. Leukemia 2003; 17: 811–813.

    Article  CAS  Google Scholar 

  17. Goterris R, Hernandez-Boluda JC, Teruel A, Gomez C, Lis MJ, Terol MJ et al. Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers. Bone Marrow Transplant 2005; 36: 847–853.

    Article  CAS  Google Scholar 

  18. Rick O, Beyer J, Kingreen D, Kuhl JS, Zingsem J, Huhn D et al. Successful autologous bone marrow rescue in patients who failed peripheral blood stem cell mobilization. Ann Hematol 2000; 79: 681–686.

    Article  CAS  Google Scholar 

  19. Watts MJ, Ings SJ, Flynn M, Dodds D, Goldstone AH, Linch DC . Remobilization of patients who fail to achieve minimal progenitor thresholds at the first attempt is clinically worthwhile. Br J Haematol 2000; 111: 287–291.

    Article  CAS  Google Scholar 

  20. Koc ON, Gerson SL, Cooper BW, Laughlin M, Meyerson H, Kutteh L et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 2000; 18: 1824–1830.

    Article  CAS  Google Scholar 

  21. Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994; 12: 2176–2186.

    Article  CAS  Google Scholar 

  22. Ali MY, Oyama Y, Monreal J, Winter JN, Tallman MS, Williams SF et al. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant 2003; 31: 861–864.

    Article  CAS  Google Scholar 

  23. Waples JM, Moreb JS, Sugrue M, Belanger G, Kubilis P, Lynch JW et al. Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. Bone Marrow Transplant 1999; 23: 867–873.

    Article  CAS  Google Scholar 

  24. Sugrue MW, Williams K, Pollock BH, Khan S, Peracha S, Wingard JR et al. Characterization and outcome of ‘hard to mobilize’ lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2000; 39: 509–519.

    Article  CAS  Google Scholar 

  25. Flomenberg N, Devine SM, DiPersio JF, Liesveld JL, McCarty JM, Rowley SD et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867–1874.

    Article  CAS  Google Scholar 

  26. Grignani G, Perissinotto E, Cavalloni G, Carnevale Schianca F, Aglietta M . Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma. J Clin Oncol 2005; 23: 3871–3872.

    Article  Google Scholar 

  27. Holtan SG, Porrata LF, Micallef IN, Padley DJ, Inwards DJ, Ansell SA et al. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2007; 7: 315–318.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA

    M Tomblyn, L J Burns, B Blazar, J Wagner, C Lee, T Rogers, P McGlave, J S Miller & D J Weisdorf

Authors
  1. M Tomblyn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L J Burns
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B Blazar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Rogers
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P McGlave
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J S Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D J Weisdorf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Tomblyn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tomblyn, M., Burns, L., Blazar, B. et al. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma. Bone Marrow Transplant 40, 111–118 (2007). https://doi.org/10.1038/sj.bmt.1705708

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705708

Keywords

This article is cited by

Search

Advanced search

Quick links